Shanghai Semro Biotechnology

Semro Biotechnology is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to developing innovative small molecule drugs for pain, cough, and other sensory system disorders. The company's research focuses on high-value ion channel targets, including P2X3, Nav1.7, and TRPA1, to address conditions with significant unmet medical needs. Its lead program, SR419, is a highly selective P2X3 receptor antagonist currently undergoing Phase 2 clinical trials for refractory chronic cough and endometriosis-associated pain. Semro's pipeline also includes SR701, a Nav1.7 inhibitor for neuropathic pain, and SR1375, a TRPA1 antagonist for pruritus and inflammatory pain. Supported by prominent venture capital firms, the company aims to provide effective and safe therapeutic options for patients suffering from chronic sensory dysfunction globally.